Esperion Therapeutics to be acquired by ARCHIMED for $3.16 per share cash plus up-to-$100M CVRs
- Transaction values Esperion at up to approximately $1.1B including cash consideration and contingent value rights.
- CVR pays $40M if 2027 U.S. Nexletol/Nexlizet net sales exceed $350M under the definitive agreement.
- Additional $60M CVR payment triggered if Enbumyst U.S. sales top $160M by the end of 2030.
No comments:
Post a Comment